

1638

FEATURE OF FUND

This fund aims to track the performance of TOPIX-17 PHARMACEUTICAL Index

FUND PROFILE (as of Dec 28, 2018)

NAV (per 1 units) ¥20,734

Total Net Asset ¥674 mil.

Total No. of Holdings 40

Ticker Code 1638

Stock Exchange Tokyo Stock Exchange

Board Lot Size 1 units

Inception Date July 22, 2008

Listing Date July 23, 2008

Trust Fee See p.2 for details.

Financial Disclosure Twice yearly
Dividend Date January 20th, July 20th.

Term of Trust Infinite


Investment Manager Daiwa Asset Management Co. Ltd.

Trustee Sumitomo Mitsui Trust Bank, Limited.

Performance

(as of Dec 28, 2018)

	1month	3months	6months	1year	3years	5years
FUND	-15.8 %	-21.1 %	-9.3 %	-5.4 %	-1.8 %	+53.9 %
TOPIX-17 PHARMACEUTICAL Index	-15.9 %	-21.2 %	-10.0 %	-6.9 %	-7.3 %	+39.9 %



Dividend Record							
Settlement Term	(15/07)	(16/01)	(16/07)	(17/01)	(17/07)	(18/01)	(18/07)
Dividend (per 1 units)	184.0	187.0	192.0	193.0	199.0	230.0	202.0

Total dividend since inception: ¥3,580.0

Portfolio Allocation

(as of Dec 28, 2018)

Asset Allocation		% of NAV
Common Stock		98.9%
Stock Futures		1.1%
REITs, Preferred Securities		---
Call Loan, Others		1.1%

Sector Allocation (Top 5)		% of NAV
1	Pharmaceutical	98.9%
2		
3		
4		
5		
Total		98.9%

Portfolio Holdings

(as of Dec 28, 2018)

		TOP 20 Holdings	% of NAV
1	4502	TAKEDA PHARMACEUTICAL	13.9623%
2	4503	ASTELLAS PHARMA	12.3098%
3	4523	EISAI	9.7129%
4	4568	DAIICHI SANKYO	9.5848%
5	4578	OTSUKA HOLDINGS	8.1326%
6	4507	SHIONOGI	7.8154%
7	4519	CHUGAI PHARMACEUTICAL	6.3421%
8	4528	ONO PHARMACEUTICAL	5.0628%
9	4536	SANTEN PHARMACEUTICAL	2.8708%
10	4151	KYOWA HAKKO KIRIN	2.4961%
11	4506	SUMITOMO DAINIPPON PHARMA	2.4890%
12	4581	TAISHO PHARMACEUTICAL HOLDINGS	2.2911%
13	4587	PEPTIDREAM	1.9317%
14	4516	NIPPON SHINYAKU	1.7630%
15	4530	HISAMITSU PHARMACEUTICAL	1.7111%
16	4508	MITSUBISHI TANABE PHARMA	1.5716%
17	4527	ROHTO PHARMACEUTICAL	1.4688%
18	---	FUTURE	1.1079%
19	4555	SAWAI PHARMACEUTICAL	1.0087%
20	4540	TSUMURA	0.9065%
Total			94.54%

* Fund performance assumes that dividends (before taxes) being reinvested in the fund, and is different from actual rate of return to investors.

* NAV value is calculated after deducting trust fees.

* In the graph, the value of TOPIX-17 PHARMACEUTICAL Index is modified to match the fund NAV at the time of inception.

* Fund dividend is decided by the investment management company based on dividend policy. The amount of fund dividend is not guaranteed.

There may be no dividend payable in some circumstances.

* Performance and data above are based on past information and neither guarantee or promise future performance.

* In case there exists any open position of eligible futures for the fund, the total number of composition ratio by asset class is not shown.

Disclaimer: Warning before handling this material

This material was prepared by Daiwa Asset Management Co. Ltd. to provide information about its funds' performance and other operation-related facts. Potential investors should refer to and read the prospectus of such fund product for more detailed information prior to their investment decision. Since investment trusts will invest in stocks whose prices fluctuate, the NAV of this fund could possibly decline and cause a loss in investment. The investors' principals thus are not guaranteed and the fund contains risk that the NAV may fall below its par value. All the gains and losses accrued to the trust assets will be attributable to the investors. Investment trusts are different from deposits and insurance policies. Investment trusts are not protected by the Deposit Insurance Corporation of Japan and insurance policyholders protection corporations. Investment trusts which are not purchased from securities companies are not protected by the Japan Investor Protection Fund. The information, statements, forecasts and projections contained herein, including any expression of opinion, are based upon sources believed to be reliable, but their accuracy, correctness or completeness are not guaranteed. The performance of investments, if referred to herein, is based on past data and is neither necessarily an indication nor a guarantee of future performance of investments. The performance data in this material does not consider any tax or fees if there were any, and will not provide a final return for potential investors. Daiwa Asset Management Co. Ltd. made all reasonable efforts to ensure that the information contained herein is current, but it is subject to change without notice. The dividend amount is to be determined, based on the dividend distribution policy of such fund product, by the investment manager, who will not promise or guarantee any fixed amount of dividend before investment. In some cases, the investment manager might decide to skip a dividend payment for the correspondent period due to performance reason.

Investment Risks

The Fund will invest in financial instruments whose prices fluctuate and as a result the NAV per unit of the Fund will also fluctuate. Therefore the invested amount will not be guaranteed and a loss of principal may be caused. All the gains and losses accrued to the trust assets will be attributable to the investors. Investment trusts are not deposits.

Major factors to cause fluctuation of NAV per unit:

1. Stock Price Volatility (Price Volatility Risks, Credit Risks): Stock price changes based on the political and economic conditions, operating results of the issuer, and market supply and demand for the security. If the issuer becomes operationally distressed or goes bankrupt, all or part of invested amount might not be returned. If the price of stocks included in the trust assets falls, the NAV per unit may fall below the invested amount.
2. Other risks: When the trust assets of the Fund are invested in money market instruments such as call loans and/or certificates of deposit, losses may accrue due to default of the issuers of such instruments (the Credit Risk). This may cause the NAV per unit to decline.

The performance of the NAV may not completely match that of the index. The factors to cause fluctuation of NAV per unit are not limited to those mentioned above.

Fee Structure

<Fees directly charged to customers>

- ◆ Subscription commission: Determined by the Distributor. (Subscription Commission is a consideration for explanation of products, provision of product information and investment information, and execution of application at the time of the subscription of the Fund)
- ◆ Redemption Fee: Nil
- ◆ Exchange commission: Determined by the Distributor.
(Exchange Commission is a consideration for administrative procedures for exchange of units of the Fund.)

<Fees indirectly charged during holding period>

◆ Management Fee (Trust Fee):

Trust fee is calculated daily as sum of 1 and 2 as shown below during the holding period.

1. The amount obtained by multiplying the total net assets of the trust assets by the ratio up to 0.1944% per annum (0.18% before tax)
2. The amount obtained by multiplying lending charges due to lending of stocks held in the trust assets by up to 54% (50% before tax)

◆ Other Expenses and Brokerage Commissions

Fund Listing Expenses and Annual Fees for Use of Trademarks of the Index with tax levied on them can be borne by the unitholders, and can be paid from the trust assets.

Commissions associated with securities transactions (including brokerage commissions on trade of securities, fees for future transactions and option transactions) and auditing fees shall be charged to the trust assets.

※As expenses for brokerage commissions on trade of securities, etc. shall vary depending on circumstances, specific rate of fees or the maximum amounts thereof cannot be disclosed in advance.

※Please see further details described under "Expenses and Taxes of the Fund" in the Prospectus.

About the copyright of the index

1. TOPIX-17 PHARMACEUTICAL Index Value and the TOPIX and TOPIX-17 PHARMACEUTICAL Trademarks are the intellectual property rights owned by the Tokyo Stock Exchange, Inc. All rights relating to TOPIX-17 PHARMACEUTICAL, including calculation, publication and use of the TOPIX-17 PHARMACEUTICAL Index Value as well as those relating to the TOPIX and TOPIX-17 PHARMACEUTICAL Trademarks belong to the Tokyo Stock Exchange, Inc.
2. The Tokyo Stock Exchange, Inc. reserves the rights to change the methods of calculation or publication, to cease the calculation or publication of the TOPIX-17 PHARMACEUTICAL Index Value or to change the TOPIX and TOPIX-17 PHARMACEUTICAL Trademarks or cease the use thereof.
3. Tokyo Stock Exchange, Inc. makes no warranty or representation whatsoever, either as to the results stemmed from the use of the TOPIX-17 PHARMACEUTICAL Index Value and the TOPIX and TOPIX-17 PHARMACEUTICAL Trademarks or as to the figure at which the TOPIX-17 PHARMACEUTICAL Index Value stands on any particular day.
4. The Tokyo Stock Exchange, Inc. does not guarantee the accuracy or completeness of the TOPIX-17 PHARMACEUTICAL Index Value and data contained therein. Further, the Tokyo Stock Exchange, Inc. shall not be liable for the miscalculation, incorrect publication, delayed or interrupted publication of the TOPIX-17 PHARMACEUTICAL Index Value.
5. The Daiwa ETF TOPIX-17 PHARMACEUTICAL not in any way sponsored, endorsed or promoted by the Tokyo Stock Exchange, Inc.
6. The Tokyo Stock Exchange, Inc. does not bear any obligation to give an explanation of the Daiwa ETF TOPIX-17 PHARMACEUTICAL or an advice on investments in the Daiwa ETF TOPIX-17 PHARMACEUTICAL to any purchaser of the Daiwa ETF TOPIX-17 PHARMACEUTICAL or to the public.
7. The Tokyo Stock Exchange, Inc. does not consider the needs of purchasers of the Daiwa ETF TOPIX-17 PHARMACEUTICAL for the composition of stocks that calculate the index value of TOPIX-17 PHARMACEUTICAL.
8. Including but not limited to the foregoing, the Tokyo Stock Exchange, Inc. shall not be responsible for any damage resulting from the issue and sale of the Daiwa ETF TOPIX-17 PHARMACEUTICAL.